To determine whether Gamitrinib could potentiate the efficacy of 6-thio-dG in melanoma cells lacking NRAS mutations, we treated NRAS-WT melanoma cells with the nucleoside analog or the mitochondrial inhibitor as single agents or in combination (Fig. 5). This evidence concerns the gene NRAS and melanoma.